DR. CECILIA YSHII TAMASHIRO M.D.
Prescription History 1750518080
Internal Medicine - Pulmonary Disease in Springfield, MO

NPI Status: Active since June 12, 2009

Contact Information

3800 S NATIONAL AVE STE 510
SPRINGFIELD, MO
ZIP 65807
Phone: (417) 875-3460
Fax: (417) 875-2601

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CECILIA YSHII TAMASHIRO M.D., an active Pulmonary Disease specialist practicing in Springfield, MO. Our medical registry currently tracks 15 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 374 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 78 claims alone.


Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 20.0
Days Supply 600
MO State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills23.9
Peer Average Days Supply714
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,301.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$858.43

State Avg Cost Per Claim

$599.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 78
30-Day Fills 101.1
Days Supply 2,685
MO State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills85.2
Peer Average Days Supply2,098
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,660.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.11

State Avg Cost Per Claim

$46.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
MO State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills42.5
Peer Average Days Supply1,267
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,066.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$504.78

State Avg Cost Per Claim

$568.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 25.2
Days Supply 691
MO State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills39.5
Peer Average Days Supply332
Conservative Utilization

This provider writes prescriptions for this formulation 48.6% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $506.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.66

State Avg Cost Per Claim

$10.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 46.2
Days Supply 1,369
MO State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills43.6
Peer Average Days Supply1,305
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,007.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$789.68

State Avg Cost Per Claim

$753.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 132
MO State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills35.2
Peer Average Days Supply491
Conservative Utilization

This provider writes prescriptions for this formulation 46.9% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $192.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.34

State Avg Cost Per Claim

$24.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
MO State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply923
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,923.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$378.71

State Avg Cost Per Claim

$448.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 30
30-Day Fills 70.0
Days Supply 2,098
MO State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills146.3
Peer Average Days Supply4,310
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.9% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $423.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.11

State Avg Cost Per Claim

$18.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
MO State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply992
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.4% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $192,889.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,837.68

State Avg Cost Per Claim

$12,517.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Omeprazole

Generic Formulation: OmeprazoleSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 22.0
Days Supply 660
MO State Average Benchmarks
Peer Average Claims124.0
Peer Average 30-Day Fills260.1
Peer Average Days Supply7,664
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.1% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $111.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.97

State Avg Cost Per Claim

$14.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Therapeutic Applications

Omeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). If you are self-treating with this medication, over-the-counter omeprazole products are used to treat frequent heartburn (occurring 2 or more days a week). Since it may take 1 to 4 days to have full effect, these products do not relieve heartburn right away. For over-the-counter products, carefully read the package instructions to make sure the product is right for you. Check the ingredients on the label even if you have used the product before. The manufacturer may have changed the ingredients. Also, products with similar brand names may contain different ingredients meant for different purposes. Taking the wrong product could harm you.

Pantoprazole Sodium

Generic Formulation: Pantoprazole SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.8
Days Supply 593
MO State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills187.2
Peer Average Days Supply5,452
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.6% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $172.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.25

State Avg Cost Per Claim

$15.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Therapeutic Applications

Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 44.0
Days Supply 981
MO State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills61.5
Peer Average Days Supply1,100
Conservative Utilization

This provider writes prescriptions for this formulation 25.5% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $540.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.23

State Avg Cost Per Claim

$6.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 510
MO State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills36.3
Peer Average Days Supply1,087
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.7% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,440.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$858.20

State Avg Cost Per Claim

$659.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 26
30-Day Fills 34.0
Days Supply 1,020
MO State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills52.8
Peer Average Days Supply1,581
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,777.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$529.89

State Avg Cost Per Claim

$518.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 45.0
Days Supply 1,350
MO State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills69.0
Peer Average Days Supply2,066
Conservative Utilization

This provider writes prescriptions for this formulation 34.5% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,461.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$873.94

State Avg Cost Per Claim

$817.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. CECILIA YSHII TAMASHIRO M.D. provides transparency into local medical care patterns within Springfield, MO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.